Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Novel agent combination therapies in melanoma: talimogene laherparepvec, PV-10 & IMO-2125

Paolo Ascierto • 1 Jun 2018
ASCO 2018
Melanoma Skin Cancer IMO-2125 Ipilimumab Pembrolizumab Talimogene laherparepvec
ILLUMINATE-204 KEYNOTE-034

The treatment of melanoma is undergoing exciting advancements, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy. Dr Ascierto highlights a promising area for further development: combination therapy. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, he highlights the different combinations to be considered. He first points towards the combination of talimogene laherparepvec with ipilimumab (NCT01740297), and a newer combination with pembrolizumab (KEYNOTE-034; NCT02263508), before considering the investigational drug PV-10 (NCT02288897), and the TLR-9 antagonist IMO-2125 in combination with ipilimumab or pembrolizumab (ILLUMINATE-204; NCT02644967).

More from Paolo Ascierto

What is the importance of CTLA-4 inhibition in treating melanoma?
1:05
What is the importance of CTLA-4 inhibition in treating melanoma?
Paolo Ascierto • 20 Oct 2025
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
2:55
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
Paolo Ascierto • 20 Oct 2025
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
2:31
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
Paolo Ascierto • 20 Oct 2025
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
2:03
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
Paolo Ascierto • 21 Oct 2023

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals